Liposomal honokiol, a potent anti-angiogenesis agent, in combination with radiotherapy produces a synergistic antitumor efficacy without increasing toxicity.
10.3858/emm.2008.40.6.617
- Author:
Jia HU
1
;
Li juan CHEN
;
Li LIU
;
Xiang CHEN
;
Ping li CHEN
;
Guang YANG
;
Wen li HOU
;
Ming Hai TANG
;
Fan ZHANG
;
Xian Huo WANG
;
Xia ZHAO
;
Yu Quan WEI
Author Information
1. State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University, Chengdu, China. lijuan17@hotmail.com
- Publication Type:Original Article ; Research Support, Non-U.S. Gov't
- Keywords:
angiogenesis inhibitors;
honokiol;
liposomes;
radiation tolerance;
radiotherapy
- MeSH:
Angiogenesis Inhibitors/administration & dosage/*therapeutic use;
Animals;
Apoptosis;
Biphenyl Compounds/administration & dosage/*therapeutic use;
Carcinoma, Lewis Lung/drug therapy/radiotherapy/*therapy;
Cell Cycle/drug effects/radiation effects;
Cell Line, Tumor;
Combined Modality Therapy;
Humans;
Lignans/administration & dosage/*therapeutic use;
Liposomes;
Lung Neoplasms/drug therapy/radiotherapy/*therapy;
Magnolia/chemistry;
Mice;
Neoplasm Transplantation;
Neovascularization, Pathologic/drug therapy/radiotherapy;
Radiation Tolerance;
Transplantation, Heterologous
- From:Experimental & Molecular Medicine
2008;40(6):617-628
- CountryRepublic of Korea
- Language:English
-
Abstract:
Honokiol is an active compound purified from magnolia that has been shown to induce cell differentiation, apoptosis, and anti-angiogenesis effects, as well as an enhancement in tumor growth delay in combination with chemotherapeutic agents in several mouse xenograft models. Our goal was to investigate the radiosensitization effect of honokiol on lung carcinoma. The radiosensitization effect of liposomal honokiol in Lewis lung carcinoma cells (LL/2) was analyzed using an in vitro clonogenic survival assay. For an in vivo study, Lewis lung carcinoma-bearing C57BL/6 mice were treated with either liposomal honokiol at 25 mg/kg or 5 Gy of single tumor radiation, or a combination of both over 12 days of treatment. The tumor growth delay and the survival time were evaluated. In addition, histological analysis of tumor sections was performed to examine changes by detecting the microvessel density and apoptosis in tumor tissues. In the clonogenic survival assay, LL/2 cells treated with IC50 Lipo-HNK for 24 h showed a radiation enhancement ratio of 1.9. After 12 days of combination treatment, the tumor volume decreased 78% and produced an anti-tumor activity 1.3-fold greater than a predicted additive effect of honokiol and radiation alone. This combination treatment also caused an 8.7 day delay in tumor growth. The cell cycle distribution and histological analysis demonstrated that liposomal honokiol has an anti-tumor effect via inducing apoptosis and inhibiting angiogenesis. Liposomal honokiol can enhance tumor cell radiosensitivity in vitro and in vivo, indicating that radiotherapy combined with liposomal honokiol can lead to greater anti-tumor efficacy.
